6.2.1.1. watchful waiting. watchful waiting refers conservative management patients deemed unsuitable curative treatment outset. aim ww balance potential harms benefits early hormonal treatment, patients clinically ‘watched’ development local systemic progression (imminent) disease-related complaints, stage treated palliatively according symptoms order maintain qol. traditionally ww meant waiting symptoms tumour develop has, practices, included regular follow-up active way. however, today evidence early hormonal treatment could prolong short term survival (within years) locally advanced disease, patients psadt < twelve months, psa-values 30-50 ng/ml . active follow-up men ww could therefore beneficial, local progression (often associated higher isup grade group), start metastatic spread, detected present significant symptoms. hormonal treatment could considered symptoms emerge. ww strategy therefore individualised planned together patient. biannual psa, annual period stable disease, followed dre psa rises significantly, could value, especially men life expectancy > five years unsuitable curative treatment. two rcts one cochrane review comparing outcomes ww rp. spcg-4 study rct pre-psa era, randomising patients either ww rp . study found rp provide superior css, os progression-free survival (pfs) compared ww median follow-up 23.6 years (range 3 weeks–28 years). however, benefit favour rp ww apparent ten years. pivot trial, rct conducted early psa era, made similar comparison rp vs. ww 731 men (50% nonpalpable disease) contrast spcg-4, found little, no, benefit rp (cumulative incidence all-cause death, rp vs. observation: 68% vs. 73%; rr: 0.92, 95% ci: 0.84–1.01) within median follow-up period 18.6 years (interquartile range, 16.6 20 years) . exploratory subgroup analysis showed borderline benefit rp marked intermediate-risk disease (rr: 0.84, 95% ci: 0.73–0.98) benefit patients low- high-risk disease. overall, adverse effects health related qol (hrqol) psychological well-being apparent first five years . however, one criticisms pivot trial relatively high overall mortality rate ww group compared contemporary series. cochrane review performed pooled analysis rcts comparing rp vs. ww . three studies included; previously mentioned spcg-4 pivot veteran’s administration cooperative urological research group (vacurg) study conducted pre-psa era . authors found rp compared ww reduced time death cause (hr: 0.79, 95% ci: 0.70–0.90), time death pca (hr: 0.57, 95% ci: 0.44–0.73) time metastatic progression (hr: 0.56, 95% ci: 0.46–0.70) 29 years’ follow-up. however, rp associated higher rates urinary incontinence (rr: 3.97, 95% ci: 2.34–6.74) ed (rr: 2.67, 95% ci: 1.63–4.38). overall evidence indicates men asymptomatic, clinically localised pca, life expectancy < ten years based comorbidities and/or age, oncological advantages active treatment ww unlikely relevant them. consequently, ww adopted patients. assistance estimating life expectancy health status see section 5.4.